An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-AK0529 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2018
At a glance
- Drugs AK 0529 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Ark Biosciences
- 10 Sep 2018 Status changed from active, no longer recruiting to completed.
- 29 Jun 2018 Planned End Date changed from 1 May 2018 to 31 Aug 2018.
- 29 Jun 2018 Status changed from not yet recruiting to active, no longer recruiting.